<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096730</url>
  </required_header>
  <id_info>
    <org_study_id>GWang003</org_study_id>
    <nct_id>NCT03096730</nct_id>
  </id_info>
  <brief_title>Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia</brief_title>
  <official_title>The Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia in Patients Undergoing Gynecological Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore and compare antihyperalgesic effects of Dexmedetomidine,Nalmefene,and a&#xD;
      combination of both received before anesthesia induction.&#xD;
&#xD;
      To evaluate and examine the incidence of adverse effects with the purpose of selecting the&#xD;
      optimum dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are a dramatically increasing number of evidences that administration of the potent,&#xD;
      ultra-short-acting opioid remifentanil seems to cause opioid-induced hyperalgesia (OIH) more&#xD;
      frequently and predictably compared with the others, likely due to its rapid onset and&#xD;
      offset. Therefore, prophylaxis of remifentanil induced hyperalgesia is indispensable to&#xD;
      postoperative comfort and satisfaction.&#xD;
&#xD;
      There is no denying the fact that OIH is related to central glutaminergic system and&#xD;
      N-methyl-d-aspartate(NMDA)receptor-activation induced central sensitization. Dexmedetomidine&#xD;
      is an 2-adrenergic agonist that has been shown to synergize with opioids. Dexmedetomidine&#xD;
      inhibits NMDAR excitability by reducing the phosphorylation of N-methyl-D-aspartate receptor&#xD;
      2B subunit phosphorylation of spinal dorsal horn induced by remifentanil, thereby achieving&#xD;
      the goal of reducing OIH. Nalmefene is a pure opioid receptor antagonist that antagonizes the&#xD;
      Mu receptor, alleviating the central sensitization of NMDA, thereby reducing OIH. At the same&#xD;
      time reported in the literature, opioid receptor has a bimode：On the one hand can be mediated&#xD;
      by Gs protein-mediated pain, respiratory depression, nausea and vomiting, etc ; on the other&#xD;
      hand can be coupled with Gi / Go protein mediated analgesic effect. Low-dose nalmefene&#xD;
      (&lt;1.0ug / kg) and other opioid receptor antagonists can antagonize the role of Gs&#xD;
      protein-coupled opioid receptors, blocking the pathway of opioid excitatory effects, thereby&#xD;
      reducing the incidence of adverse reactions.The following study is carried out to evaluate&#xD;
      whether dexmedetomidine combined with nalmefene can be safely and effectively applied to&#xD;
      prevent postoperative hyperalgesia induced by remifentanil in patients undergoing&#xD;
      Laparoscopic gynecological surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Actual">December 30, 2017</completion_date>
  <primary_completion_date type="Actual">December 20, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament at 24 hours postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalized Area of Hyperalgesia Around the Incision</measure>
    <time_frame>1hours,3hours，6hours，12hours，24hours after surgery</time_frame>
    <description>The skin around the incision is stimulated in steps of 5 mm at intervals of 1 s starting outside of the hyperalgesic area in the direction of the incision. The distance from the incision to the first point where a 'painful', 'sore' or 'sharper' feeling occurred is measured and noted. This measurement is repeated at predefined radial lines around the incision. To eliminate the variable length of incision, this length is subtracted from the longer diameter leaving four radial distances from the end and from the middle of the incision. The normalized area of hyperalgesia is calculated by summing up the areas of the remaining four triangles measured by and Von Frey filament.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score (Numerical Rating Scale)</measure>
    <time_frame>1hours,3hours，6hours，12hours，24hours after surgery</time_frame>
    <description>The pain score at rest was evaluated by pain 11-point numerical rating scale : 0 = no pain, 10 = greatest imaginable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of First Postoperative Analgesic Requirement</measure>
    <time_frame>postoperative 1 hours</time_frame>
    <description>First postoperative pain (NRS≥5) is initially controlled by titration of sufentanyl.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Sufentanyl Consumption</measure>
    <time_frame>1hours,3hours，6hours，12hours，24hours after surgery</time_frame>
    <description>Each patient was administered analgesics using a PCA pump containing sufentanil (100μg) in normal saline at a total volume of 100 ml after leaving post-anaesthesia care unit . This device was set to deliver a basal infusion of 2 ml/h and bolus doses of 0.5 ml with a 15-min lockout period. Sufentanyl cumulative consumption is recorded 24 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Side Effects</measure>
    <time_frame>24 hours</time_frame>
    <description>Occurrence of side effects: nausea, vomiting, dizziness, headache, shivering, pruritus，hypotention/hypertention，bradycardia/tachycardia</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Pain</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sufentanil</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Normal saline is intravenously admistrated before anesthesia induction and intraoperative pain management was with sufentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine is intravenously administrated at a dose of 0.5ug/kg 10min before anesthesia induction and intraoperative pain management was with remifentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nalmefene</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nalmefene is intravenously administrated at a dose of 0.2ug/kg before anesthesia induction and intraoperative pain management was with remifentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine-Nalmefene</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A dose of 0.1ug/kg nalmefene and a dose of 0.25ug/kg dexmedetomidine for 10 minutes before anesthesia induction and intraoperative pain management was with remifentanil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline is intravenously administrated before anesthesia induction</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_label>Sufentanil</arm_group_label>
    <other_name>0. 9% Sodium Chloride Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil is intravenously administrated</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_label>Dexmedetomidine-Nalmefene</arm_group_label>
    <arm_group_label>Nalmefene</arm_group_label>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>Remifentanil Hydrochloride for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>Sufentanil is intravenously administrated</description>
    <arm_group_label>Sufentanil</arm_group_label>
    <other_name>Sufentanil injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine injection</intervention_name>
    <description>Dexmedetomidine is intravenously administrated before anesthesia induction</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_label>Dexmedetomidine-Nalmefene</arm_group_label>
    <other_name>Dexmedetomidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalmefene</intervention_name>
    <description>Nalmefene is intravenously administrated before anesthesia induction</description>
    <arm_group_label>Dexmedetomidine-Nalmefene</arm_group_label>
    <arm_group_label>Nalmefene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients are scheduled to undergo Gynecological surgery under a short general&#xD;
             anesthesia of 1-3 hours.&#xD;
&#xD;
          2. American Society of Anesthesiologists physical status is I-II.&#xD;
&#xD;
          3. Written informed consent was obtained from all the subjects.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a diagnosis of Coronary heart disease, bronchial asthma, cardiac, lung,&#xD;
             hepatic and renal insufficiency.&#xD;
&#xD;
          2. Subject has a diagnosis of Severe high blood pressure , diabetes, obesity (BMI&gt;30).&#xD;
&#xD;
          3. Subject has a history of chronic pain, a history of alcohol or opioid abuse,&#xD;
             pre-existing therapy with opioids, intake of any analgesic drug within 48 h before&#xD;
             surgery.&#xD;
&#xD;
          4. .Subject has Pregnancy, psychiatric disease.&#xD;
&#xD;
          5. Subject has any contraindication for the use of patient-controlled analgesia (PCA).&#xD;
&#xD;
          6. Inability to understand the Study Information Sheet and provide a written consent to&#xD;
             take part in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang Guolin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tianjin Medical University General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <results_first_submitted>February 24, 2018</results_first_submitted>
  <results_first_submitted_qc>August 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2021</results_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Medical University General Hospital</investigator_affiliation>
    <investigator_full_name>Guolin Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Remifentanil</keyword>
  <keyword>Opioid-induced hyperalgesia</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>pain intensity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Dsuvia</mesh_term>
    <mesh_term>Nalmefene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>data not entered</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03096730/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03096730/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From February 2017 to September 2017, patients were recruited and estimated for eligibility</recruitment_details>
      <pre_assignment_details>Exclusion criteria: coronary heart disease, bronchial asthma, cardiac, lung, hepatic and renal insufficiency, severe hypertension, diabetes mellitus, psychiatric disease, obesity, a history of chronic pain, a history of alcohol or opioid abuse, pregnancy, allergy and contraindication to study drugs.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Normal Saline</title>
          <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil&#xD;
Normal saline: Normal saline is intravenously administrated before anesthesia induction&#xD;
Remifentanil: Remifentanil is intravenously administrated</description>
        </group>
        <group group_id="P2">
          <title>Sufentanil</title>
          <description>Normal saline is intravenously admistrated before anesthesia induction and intraoperative pain management was with sufentanil&#xD;
Normal saline: Normal saline is intravenously administrated before anesthesia induction&#xD;
Sufentanil: Sufentanil is intravenously administrated</description>
        </group>
        <group group_id="P3">
          <title>Dexmedetomidine</title>
          <description>Dexmedetomidine is intravenously administrated at a dose of 0.4ug/kg 10min before anesthesia induction until 30min prior to the end of surgery and intraoperative pain management was with remifentanil&#xD;
Remifentanil: Remifentanil is intravenously administrated&#xD;
Dexmedetomidine: Dexmedetomidine is intravenously administrated before anesthesia induction</description>
        </group>
        <group group_id="P4">
          <title>Nalmefene</title>
          <description>Nalmefene is intravenously administrated at a dose of 0.3ug/kg before anesthesia induction and intraoperative pain management was with remifentanil&#xD;
Remifentanil: Remifentanil is intravenously administrated&#xD;
Nalmefene: Nalmefene is intravenously administrated before anesthesia induction</description>
        </group>
        <group group_id="P5">
          <title>Dexmedetomidine-Nalmefene</title>
          <description>A dose of 0.3ug/kg nalmefene and a dose of 0.4ug/kg dexmedetomidine for 10 minutes before anesthesia induction until 30min prior to the end of surgery and intraoperative pain management was with remifentanil&#xD;
Remifentanil: Remifentanil is intravenously administrated&#xD;
Dexmedetomidine: Dexmedetomidine is intravenously administrated before anesthesia induction&#xD;
Nalmefene: Nalmefene is intravenously administrated before anesthesia induction</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal Saline</title>
          <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil&#xD;
Normal saline: Normal saline is intravenously administrated before anesthesia induction&#xD;
Remifentanil: Remifentanil is intravenously administrated</description>
        </group>
        <group group_id="B2">
          <title>Sufentanil</title>
          <description>Normal saline is intravenously admistrated before anesthesia induction and intraoperative pain management was with sufentanil&#xD;
Normal saline: Normal saline is intravenously administrated before anesthesia induction&#xD;
Sufentanil: Sufentanil is intravenously administrated</description>
        </group>
        <group group_id="B3">
          <title>Dexmedetomidine</title>
          <description>Dexmedetomidine is intravenously administrated at a dose of 0.5ug/kg 10min before anesthesia induction and intraoperative pain management was with remifentanil&#xD;
Remifentanil: Remifentanil is intravenously administrated&#xD;
Dexmedetomidine: Dexmedetomidine is intravenously administrated before anesthesia induction</description>
        </group>
        <group group_id="B4">
          <title>Nalmefene</title>
          <description>Nalmefene is intravenously administrated at a dose of 0.2ug/kg before anesthesia induction and intraoperative pain management was with remifentanil&#xD;
Remifentanil: Remifentanil is intravenously administrated&#xD;
Nalmefene: Nalmefene is intravenously administrated before anesthesia induction</description>
        </group>
        <group group_id="B5">
          <title>Dexmedetomidine-Nalmefene</title>
          <description>A dose of 0.2ug/kg nalmefene and a dose of 0.5ug/kg dexmedetomidine for 10 minutes before anesthesia induction and intraoperative pain management was with remifentanil&#xD;
Remifentanil: Remifentanil is intravenously administrated&#xD;
Dexmedetomidine: Dexmedetomidine is intravenously administrated before anesthesia induction&#xD;
Nalmefene: Nalmefene is intravenously administrated before anesthesia induction</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="27"/>
            <count group_id="B6" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="27"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="27"/>
                    <count group_id="B6" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.0" spread="5.0"/>
                    <measurement group_id="B2" value="46.0" spread="8.0"/>
                    <measurement group_id="B3" value="45.0" spread="12"/>
                    <measurement group_id="B4" value="47.0" spread="10"/>
                    <measurement group_id="B5" value="46.0" spread="9"/>
                    <measurement group_id="B6" value="46.2" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="27"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="27"/>
                    <count group_id="B6" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="27"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="27"/>
                    <count group_id="B6" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="27"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="27"/>
                    <count group_id="B6" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="7"/>
                    <measurement group_id="B2" value="57" spread="8"/>
                    <measurement group_id="B3" value="59" spread="7"/>
                    <measurement group_id="B4" value="58" spread="5"/>
                    <measurement group_id="B5" value="60" spread="8"/>
                    <measurement group_id="B6" value="59" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm</title>
        <description>The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament at 24 hours postoperatively</description>
        <time_frame>24 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
            <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil&#xD;
Normal saline: Normal saline is intravenously administrated before anesthesia induction&#xD;
Remifentanil: Remifentanil is intravenously administrated</description>
          </group>
          <group group_id="O2">
            <title>Sufentanil</title>
            <description>Normal saline is intravenously admistrated before anesthesia induction and intraoperative pain management was with sufentanil&#xD;
Normal saline: Normal saline is intravenously administrated before anesthesia induction&#xD;
Sufentanil: Sufentanil is intravenously administrated</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine</title>
            <description>Dexmedetomidine is intravenously administrated at a dose of 0.4ug/kg 10min before anesthesia induction until 30min prior to the end of surgery and intraoperative pain management was with remifentanil&#xD;
Remifentanil: Remifentanil is intravenously administrated&#xD;
Dexmedetomidine: Dexmedetomidine is intravenously administrated before anesthesia induction</description>
          </group>
          <group group_id="O4">
            <title>Nalmefene</title>
            <description>Nalmefene is intravenously administrated at a dose of 0.3ug/kg before anesthesia induction and intraoperative pain management was with remifentanil&#xD;
Remifentanil: Remifentanil is intravenously administrated&#xD;
Nalmefene: Nalmefene is intravenously administrated before anesthesia induction</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine-Nalmefene</title>
            <description>A dose of 0.3ug/kg nalmefene and a dose of 0.4ug/kg dexmedetomidine for 10 minutes before anesthesia induction until 30min prior to the end of surgery and intraoperative pain management was with remifentanil&#xD;
Remifentanil: Remifentanil is intravenously administrated&#xD;
Dexmedetomidine: Dexmedetomidine is intravenously administrated before anesthesia induction&#xD;
Nalmefene: Nalmefene is intravenously administrated before anesthesia induction</description>
          </group>
        </group_list>
        <measure>
          <title>Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm</title>
          <description>The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament at 24 hours postoperatively</description>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" spread="6.0"/>
                    <measurement group_id="O2" value="88.2" spread="23.40"/>
                    <measurement group_id="O3" value="73.0" spread="3.2"/>
                    <measurement group_id="O4" value="67.2" spread="3.3"/>
                    <measurement group_id="O5" value="74.0" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normalized Area of Hyperalgesia Around the Incision</title>
        <description>The skin around the incision is stimulated in steps of 5 mm at intervals of 1 s starting outside of the hyperalgesic area in the direction of the incision. The distance from the incision to the first point where a 'painful', 'sore' or 'sharper' feeling occurred is measured and noted. This measurement is repeated at predefined radial lines around the incision. To eliminate the variable length of incision, this length is subtracted from the longer diameter leaving four radial distances from the end and from the middle of the incision. The normalized area of hyperalgesia is calculated by summing up the areas of the remaining four triangles measured by and Von Frey filament.</description>
        <time_frame>1hours,3hours，6hours，12hours，24hours after surgery</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score (Numerical Rating Scale)</title>
        <description>The pain score at rest was evaluated by pain 11-point numerical rating scale : 0 = no pain, 10 = greatest imaginable pain.</description>
        <time_frame>1hours,3hours，6hours，12hours，24hours after surgery</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of First Postoperative Analgesic Requirement</title>
        <description>First postoperative pain (NRS≥5) is initially controlled by titration of sufentanyl.</description>
        <time_frame>postoperative 1 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Sufentanyl Consumption</title>
        <description>Each patient was administered analgesics using a PCA pump containing sufentanil (100μg) in normal saline at a total volume of 100 ml after leaving post-anaesthesia care unit . This device was set to deliver a basal infusion of 2 ml/h and bolus doses of 0.5 ml with a 15-min lockout period. Sufentanyl cumulative consumption is recorded 24 hours postoperatively</description>
        <time_frame>1hours,3hours，6hours，12hours，24hours after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Side Effects</title>
        <description>Occurrence of side effects: nausea, vomiting, dizziness, headache, shivering, pruritus，hypotention/hypertention，bradycardia/tachycardia</description>
        <time_frame>24 hours</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Incidence of adverse effects was evaluated during 24h after surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Normal Saline</title>
          <description>Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil&#xD;
Normal saline: Normal saline is intravenously administrated before anesthesia induction&#xD;
Remifentanil: Remifentanil is intravenously administrated</description>
        </group>
        <group group_id="E2">
          <title>Sufentanil</title>
          <description>Normal saline is intravenously admistrated before anesthesia induction and intraoperative pain management was with sufentanil&#xD;
Normal saline: Normal saline is intravenously administrated before anesthesia induction&#xD;
Sufentanil: Sufentanil is intravenously administrated</description>
        </group>
        <group group_id="E3">
          <title>Dexmedetomidine</title>
          <description>Dexmedetomidine is intravenously administrated at a dose of 0.4ug/kg 10min before anesthesia induction until 30min prior to the end of surgery and intraoperative pain management was with remifentanil&#xD;
Remifentanil: Remifentanil is intravenously administrated&#xD;
Dexmedetomidine: Dexmedetomidine is intravenously administrated before anesthesia induction</description>
        </group>
        <group group_id="E4">
          <title>Nalmefene</title>
          <description>Nalmefene is intravenously administrated at a dose of 0.3ug/kg before anesthesia induction and intraoperative pain management was with remifentanil&#xD;
Remifentanil: Remifentanil is intravenously administrated&#xD;
Nalmefene: Nalmefene is intravenously administrated before anesthesia induction</description>
        </group>
        <group group_id="E5">
          <title>Dexmedetomidine-Nalmefene</title>
          <description>A dose of 0.3ug/kg nalmefene and a dose of 0.4ug/kg dexmedetomidine for 10 minutes before anesthesia induction until 30min prior to the end of surgery and intraoperative pain management was with remifentanil&#xD;
Remifentanil: Remifentanil is intravenously administrated&#xD;
Dexmedetomidine: Dexmedetomidine is intravenously administrated before anesthesia induction&#xD;
Nalmefene: Nalmefene is intravenously administrated before anesthesia induction</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Guolin Wang</name_or_title>
      <organization>Tianjin Medical University General Hospita</organization>
      <phone>13002211205</phone>
      <email>1464322162@qq.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

